These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15249845)

  • 1. The economic benefits of acetylcholinesterase inhibitors for patients with Alzheimer disease and associated dementias.
    Fillit H; Hill J
    Alzheimer Dis Assoc Disord; 2004; 18 Suppl 1():S24-9. PubMed ID: 15249845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of donepezil in moderate to severe Alzheimer disease.
    Feldman H; Gauthier S; Hecker J; Vellas B; Hux M; Xu Y; Schwam EM; Shah S; Mastey V;
    Neurology; 2004 Aug; 63(4):644-50. PubMed ID: 15326236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease.
    Marin D; Amaya K; Casciano R; Puder KL; Casciano J; Chang S; Snyder EH; Cheng I; Cuccia AJ
    Int Psychogeriatr; 2003 Dec; 15(4):385-98. PubMed ID: 15000418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK.
    Ward A; Caro JJ; Getsios D; Ishak K; O'Brien J; Bullock R;
    Int J Geriatr Psychiatry; 2003 Aug; 18(8):740-7. PubMed ID: 12891643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of rivastigmine on caregiver burden associated with Alzheimer's disease in both informal care and nursing home settings.
    Grossberg GT
    Drugs Aging; 2008; 25(7):573-84. PubMed ID: 18582146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
    Lu S; Hill J; Fillit H
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States.
    Migliaccio-Walle K; Getsios D; Caro JJ; Ishak KJ; O'Brien JA; Papadopoulos G;
    Clin Ther; 2003 Jun; 25(6):1806-25. PubMed ID: 12860500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donepezil use in managed Medicare: effect on health care costs and utilization.
    Fillit H; Gutterman EM; Lewis B
    Clin Ther; 1999 Dec; 21(12):2173-85. PubMed ID: 10645761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical Treatment for Alzheimer's Disease and Related Dementias: Utilization and Disparities.
    Barthold D; Joyce G; Ferido P; Drabo EF; Marcum ZA; Gray SL; Zissimopoulos J
    J Alzheimers Dis; 2020; 76(2):579-589. PubMed ID: 32538845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France.
    Touchon J; Lachaine J; Beauchemin C; Granghaud A; Rive B; Bineau S
    Eur J Health Econ; 2014 Nov; 15(8):791-800. PubMed ID: 23928827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan.
    Fuh JL; Wang SJ
    Int J Geriatr Psychiatry; 2008 Jan; 23(1):73-8. PubMed ID: 17520661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noncognitive symptoms and long-term treatment expectations for Alzheimer disease.
    Blesa R
    Alzheimer Dis Assoc Disord; 2004; 18 Suppl 1():S9-16. PubMed ID: 15249843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Int J Technol Assess Health Care; 2002; 18(3):497-507. PubMed ID: 12391943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The needs of the caregiver in the long-term treatment of Alzheimer disease.
    Bullock R
    Alzheimer Dis Assoc Disord; 2004; 18 Suppl 1():S17-23. PubMed ID: 15249844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The costs of Alzheimer's disease and the value of effective therapies.
    Stefanacci RG
    Am J Manag Care; 2011 Nov; 17 Suppl 13():S356-62. PubMed ID: 22214393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden.
    Garfield FB; Getsios D; Caro JJ; Wimo A; Winblad B
    Pharmacoeconomics; 2002; 20(9):629-37. PubMed ID: 12141890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donepezil. Pharmacoeconomic implications of therapy.
    Foster RH; Plosker GL
    Pharmacoeconomics; 1999 Jul; 16(1):99-114. PubMed ID: 10539126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.
    Lamb HM; Goa KL
    Pharmacoeconomics; 2001; 19(3):303-18. PubMed ID: 11303418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.
    Hauber AB; Gnanasakthy A; Mauskopf JA
    Clin Ther; 2000 Apr; 22(4):439-51. PubMed ID: 10823365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An economic evaluation of donepezil in the treatment of Alzheimer's disease.
    Small GW; Donohue JA; Brooks RL
    Clin Ther; 1998; 20(4):838-50. PubMed ID: 9737841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.